Xencor (XNCR) Insider Ellen Feigal Sells $89K of Stock
Ellen Feigal sold 6,843 shares of Xencor on June 18, 2026, under a planned transaction.
Reviewed by automated data checks against the source filing. How we make and check alerts
Ellen Feigal sold 6,843 shares of Xencor, Inc. ($XNCR) at an average price of $13.06, worth about $89,369.58, on June 18, 2026. The trade was reported to the SEC in a Form 4 filing and was made under a pre-arranged Rule 10b5-1 trading plan.
Since the trade, $XNCR is up 16.6% after 1 week, up 48.8% after 1 month and up 80.8% to date (from the $12.64 close on Jun 18, 2026).
XNCR
Xencor, Inc.
Key Points
- Ellen Feigal sold 6,843 shares of Xencor, Inc. on June 18, 2026, for $89,369.58 under a planned sale.
- Shares of Xencor traded near $14.01 on Tuesday with a market cap of about $1.04 billion and no meaningful P/E ratio.
- JP Morgan maintained a hold rating on Xencor with a $14 target price, while Barclays kept a buy rating with a $27 target.
Get $XNCR trade alerts by text
We text you when insiders, Congress or big funds trade $XNCR. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Xencor, Inc. alert may contain errors. Disclosures
Ellen Feigal, an insider at Xencor, Inc., sold 6,843 shares of the company on June 18, 2026. The shares were sold at an average price of $13.06, totaling $89,369.58. This sale was part of a planned transaction under Rule 10b5-1.
Insider Buying and Selling at Xencor, Inc.
In addition to Ellen Feigal, several other insiders at Xencor have recently sold shares. On June 15, 2026, Richard Ranieri, Kevin Charles Gorman, Kurt Gustafson, and Alan Bruce Montgomery each sold shares at an average price of $12.31. Bart Jan Cornelissen, the Senior Vice President and CFO, sold 3,499 shares on April 10, 2026, at $12.29, though this was not a planned sale.
Xencor, Inc. Stock Down 43.3%
Shares of NasdaqGM:XNCR traded near $14.01 on Tuesday. Xencor has a market capitalization of approximately $1.04 billion. The company does not have a meaningful P/E ratio as it is not currently profitable. Its beta is 0.928, indicating lower volatility compared to the market. Xencor's stock has seen a 52-week low of $6.92 and a high of $18.69. The 50-day moving average is $12.16, and the 200-day moving average is $12.87. The company's current ratio stands at 6.57, with a quick ratio of 6.22 and a debt-to-equity ratio of 33.97.
Analysts Set New Price Targets
On May 11, 2026, JP Morgan maintained its hold rating on Xencor with a price target of $14. Barclays, on February 26, 2026, maintained a buy rating with a target price of $27. The consensus among analysts is a strong buy, with a mean target price of $28.50 based on 12 analyst opinions.
About Xencor, Inc.
Xencor, Inc. is a biotechnology company headquartered in Pasadena, California. It focuses on developing engineered antibodies for cancer and autoimmune diseases. The company offers treatments like Ultomiris and Monjuvi for various conditions and is working on a range of other antibody therapies. Dr. Bassil I. Dahiyat is the CEO, and the company employs around 260 people.
Bottom Line
Ellen Feigal's recent sale of Xencor shares is part of planned insider trading activity. Investors keep a close watch on insider transactions as they can provide insight into a company's prospects. However, it's important to remember that such sales do not necessarily indicate negative sentiment. Xencor, with its focus on innovative treatments, continues to be a company to watch in the biotechnology sector.
Related Filing Alerts
Source: Ellen Feigal's Form 4 filing on $XNCR (Jun 18, 2026). Find the original filing: XNCR Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts